Regencell Bioscience Holdings Limited
Price Action
Technical Summary
EMERGING TRENDRegencell Bioscience Holdings Limited is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is leading (RS Rating: 90), indicating clear outperformance against the broad market. Earnings contraction of 6% provides fundamental context to the price action. Investors should exercise caution due to high volatility (208% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $28.89 | -4.49% | BELOW |
| 50 SMA | $27.07 | +1.94% | ABOVE |
| 100 SMA | $27.39 | +0.72% | ABOVE |
| 150 SMA | $23.31 | +18.36% | ABOVE |
| 200 SMA | $20.96 | +31.61% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is RGC in an uptrend right now?
RGC has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is RGC overbought or oversold?
RGC's RSI (14) is 46. The stock is in neutral territory, neither overbought nor oversold.
Is RGC outperforming the market?
RGC has a Relative Strength (RS) Rating of 90 out of 99. Yes, RGC is a market leader, outperforming 90% of all stocks over the past 12 months.
Where is RGC in its 52-week range?
RGC is trading at $27.59, which is 33% of its 52-week high ($83.60) and 30% above its 52-week low ($3.93).
How volatile is RGC?
RGC has a Beta of 0.72 and 52-week volatility of 208%. It's less volatile than the S&P 500 - generally more stable.